JLJeffrey M. Linnen

Jeffrey M. Linnen

*This is an algorithmically generated author record based on publicly available information.

Jeffrey M. Linnen has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development and validation of a pan‐ Plasmodium molecular assay as a confirmatory method for blood donor screening

    by Pamela Milani, Li Wen, Leilani Montalvo, Sonia Bakkour Coco, Clara Di Germanio, Vanessa Bres, Manisha Yadav, Kristin Livezey, José Eduardo Levi, Jeffrey Linnen, et al.

    Background: Transfusion‐transmitted malaria remains a concern in non‐endemic regions due to asymptomatic parasitemia in donors with prior residence in or travel to malaria‐endemic areas. Nucleic acid testing (NAT)‐based screening has been proposed to mitigate this risk, and supplemental assays are needed to confirm reactive donations. We developed a pan‐ Plasmodium reverse transcription quantitative PCR (RT‐qPCR) assay with species identification capability as a supplemental tool for malaria donor screening. Study Design and Methods: The assay targets a conserved region of the 18S rRNA shared by all five human‐infecting Plasmodium species and is compatible with whole blood lysed using Grifols' parasite transport medium (PTM). Analytical performance was evaluated using in vitro transcripts and infected red blood cells (iRBCs), with the limit of detection (LoD) determined by probit analysis. Specificity was assessed against Babesia microti and 300 non‐exposed US donor samples. Clinical sensitivity was evaluated using infected specimens; species identification was performed by sequencing of RT‐qPCR amplicons. Results: The assay demonstrated high amplification efficiency (97.2%) and linearity ( R 2 = 0.99). The 95% LoD was 5.3 iRBCs/mL (95% CI: 3.2–8.6), comparable to the Procleix Plasmodium Assay. Clinical sensitivity was 100% across all five Plasmodium species, and clinical specificity was 100% (95% CI: 99–100%), with no cross‐reactivity with Babesia . Amplicon sequencing enabled accurate species‐level identification of all sequenced specimens. Discussion: This assay provides a sensitive confirmatory tool for malaria NAT‐based donor screening. Its compatibility with PTM lysates and species identification capabilities supports regulatory applications and research into asymptomatic parasitemia in semi‐immune donors.

  • Open Access

    Blood donor West Nile virus screening identifies three autochthonous Usutu virus infections in Spain

    by Teresa Jimenez‐Marco, Maria Piron, Gabriela Capllonch‐Amer, Marta Bes, Jeffrey M. Linnen, Kristin Livezey, Núria Busquets, Ana Vázquez, Laura Herrero, Mayte Pérez‐Olmeda, et al.

    Background: Considering the increase of West Nile virus (WNV) circulation in Europe, blood banks perform WNV Nucleic Acid Test testing to ensure transfusion safety during the WNV transmission season. Usutu virus (USUV), an arbovirus related to WNV, has relevant molecular and serological cross‐reactivity with WNV. Study Design and Methods: During the 2024 WNV season in Europe, 15,957 blood donations from the Balearic Islands Blood Bank and 79,400 from the Catalonia Blood Bank were tested for WNV using the Cobas WNV real‐time PCR (Roche Diagnostics, USA) and the Procleix WNV/Procleix ArboPlex transcription‐mediated assays (Grifols Diagnostic Solutions Inc., USA), respectively. Serological tests for flavivirus, PCR using USUV‐ and WNV‐specific primers, sequencing of viral RNA, and neutralization tests (NT) were performed to confirm positive results. Results: We identified three donors with USUV infection. In July, the first donor was detected in Majorca (Balearic Islands), whose infection was confirmed by NT. In September, two donors with USUV Africa 3 lineage were identified by RT‐PCR and sequencing in Catalonia. There were three USUV‐positive cases in 95,357 donations (1 in 31,786; 95% CI: 1 in 10,877 to 1 in 154,083) during the 2024 WNV season in Spain. Discussion: We report three cases of autochthonous USUV infection in blood donors from the Balearic Islands and Catalonia, two of which were infected by the USUV Africa 3 lineage. Health authorities should be aware that positive WNV screening may be due to USUV, an emerging zoonotic virus that can be underreported.


  • A novel mitigation strategy for the prevention of transfusion‐transmitted malaria

    by Laura Tonnetti, Jamel A. Groves, Deanna Self, Manisha Yadav, Bryan R. Spencer, Kristin Livezey, Jeffrey M. Linnen, Susan L. Stramer

    Background: Malaria is caused by protozoa of the genus Plasmodium and transmitted by Anopheles mosquitos. In the US, blood donors are assessed for malaria risk, including donor travel or previous residence in endemic areas and history of malaria by questionnaire and deferred for three months or three years, respectively.Methods: The Procleix Plasmodium Assay is a qualitative nucleic acid test based on transcription‐mediated amplification (TMA) for the detection of 18S ribosomal RNA of P. falciparum, P. ovale, P. vivax, P. malariae, and P. knowlesi for use on the Procleix Panther system. Analytical sensitivity was evaluated with in vitro transcripts and infected red blood cells. For clinical specificity, 12,800 individual donations and 283 pools of 16 samples from routine US donors were screened. Malaria risk was evaluated by testing 862 donors deferred for 3 years. Reactive results were confirmed with in‐house real‐time TMA assay and serology.Results: Assay sensitivity was 8.47–11.89 RNA copies/mL and 2.10–6.82 infected red cells/mL. Specificity was 99.99% in 12,800 individual donations and 100% in 283 pools of 16. Of 862 tested deferred donor samples, one donor (0.12%) confirmed positive individually and in pools; he remained confirmed positive for 13 months. The infected donor was a prior resident of a malaria‐endemic area in West Africa.Conclusions: The Procleix Plasmodium Assay showed high sensitivity and specificity and detected Plasmodium RNA in an asymptomatic presenting donor. This assay may prove helpful as a screening test versus the use of risk questions to reduce the number of donors deferred for malaria risk.


  • Clinical performance of a new multiplex assay for the detection of HIV‐1, HIV‐2, HCV, HBV, and HEV in blood donations in Catalonia (Spain)

    by Silvia Sauleda, Marta Bes, Maria Piron, Edgar Ong, Sonia Bakkour Coco, Jaume Carrió, Jeffrey M. Linnen

    Background: Commercial multiplex nucleic acid tests (NATs) for HIV‐1/HIV‐2/HCV/HBV are widely used in developed countries to screen blood donations. HEV NAT screening has been implemented in some blood banks but is tested with a different assay.Study Design and Methods: This study describes the clinical sensitivity and specificity of the Procleix® UltrioPlex E (UPxE) assay on the automated Procleix Panther® system for the simultaneous detection of HIV‐1/HIV‐2/HCV/HBV/HEV. To evaluate routine performance, 10,138 donations were tested in parallel with UPxE (in ID‐NAT) and current assays (Procleix Ultrio Elite [UE] assay in ID‐NAT and Procleix HEV assay in pool of 16). To assess clinical sensitivity, archived donations positive for HCV, HIV‐1, HBV, HEV, or occult HBV infection (OBI) were tested (n = 104–186).Results: Five donations were initially reactive (IR) with UPxE; none of them were reactive with current assays. Two of the three samples IR for HIV‐1/HIV‐2/HCV/HBV were confirmed positive for HBV (HBV NAT and/or anti‐HBV core positive) and classified as OBI. The two samples IR for HEV were confirmed positive (Procleix HEV assay in ID‐NAT and in‐house RT‐PCR HEV assay). One sample IR for HIV‐1/HIV‐2/HCV/HBV with UPxE and another with UE were not confirmed. UPxE showed a specificity of 99.99% for HIV‐1/HIV‐2/HCV/HBV and 100% for HEV. Comparable sensitivities were observed for HIV‐1, HCV, HBV, OBI, and HEV samples tested in the UPxE, UE, and Procleix HEV assays.Discussion: UPxE may provide an efficient solution for the simultaneous detection of HIV‐1, HIV‐2, HCV, HBV, and HEV in blood donations in a single test.


  • Nucleic acid testing for monkeypox in United States blood donor specimens

    by Jamel A. Groves, Laura Tonnetti, Deanna Self, Manisha C. Yadav, Kristin Livezey, Jeffery M. Linnen, Susan L. Stramer

    BackgroundThe 2022 multi-country outbreak of monkeypox (mpox) resulted in blood collection and public health agencies closely monitoring for changes in transmission dynamics that could pose a threat to the blood supply. While mpox virus (MPXV) is not known to be transfusion transmissible, there have been several studies demonstrating the detection of MPXV in blood. We evaluated the performance characteristics of a research use only (RUO) nucleic acid amplification test for MPXV. The assay was developed to detect MPXV DNA in plasma and serum specimens from human blood donors. Methods and MaterialsThe sensitivity of the RUO MPXV Assay was determined using a synthetic DNA sequence, purified full-length genomic DNA, and a chemically inactivated virus. Specificity was determined using fresh plasma samples collected from blood donors during the outbreak. Plasma samples collected from donors considered at increased risk for exposure to mpox were also tested. ResultsFor sensitivity, the 95% limit of detection (LOD) ranged from 0.26 copies/mL (inactivated virus) to 31.65 copies/mL (synthetic DNA) to 166.61 copies/mL (for full-length DNA). All donor samples tested with the RUO MPXV Assay were nonreactive, resulting in a specificity of 100% (95% CI, 99.93%-100.00%). DiscussionThe RUO MPXV Assay was developed as a potential blood donation screening assay in response to the outbreak. While not directly comparable, the 95% LOD fiducial limits obtained from partial- and full-length DNA analysis were similar to other manufacturers' MPXV assays. Additionally, this assay demonstrated high specificity for screening blood donors.


  • Open Access

    Low rate of detection of SARS-CoV-2 RNA in deceased tissue donors

    by Melissa A. Greenwald, Eduard Grebe, Valerie Green, Alyce Linthurst Jones, Jeffrey M. Linnen, Phillip Williamson, Michael P. Busch, Matthew J. Kuehnert

    Given the possibility for disease transmission, this study was performed to determine whether there is detectable SARS-CoV-2 viral RNA in the blood of deceased tissue donors. A retrospective analysis of blood samples from eligible deceased tissue donors from Oct 2019 through June 2020 was performed. Plasma aliquots were initially tested with a SARS-CoV-2 NAT Assay; positive samples were further tested using an alternate NAT and an antibody assay. The proportion of donors with confirmed RNAemia and 95% confidence intervals were computed. Of donor samples collected in 2019, 894 yielded valid results, with 6 initially positive, none of which confirmed positive by alternate NAT. Of donor samples collected in 2020, 2562 yielded valid initial NAT results, with 21 (0.8%) initially positive. Among those, 3 were confirmed by alternate NAT, 17 were not confirmed, and 1 had an invalid alternate NAT result. The rate of SARS-CoV-2 RNAemia in deceased tissue donors is approximately 1 per 1000, and it is unknown whether this RNAemia reflects the presence of infectious virus. Given these results, the risk of transmission through tissue is thought likely to be low.


  • Background rate of low‐level HCV RNA in anti‐HCV confirmed‐positive and minipool nucleic acid test‐nonreactive blood donations

    by Jamel A. Groves, Roger Y. Dodd, Xiaomei Zhu, Jeffrey M. Linnen, Susan L. Stramer

    Background In 2019, the Food and Drug Administration revised the requirement for further testing of anti-HCV-reactive donations testing nucleic acid (NAT)-nonreactive via routine mini-pool (MP)-NAT. Individual donation (ID)-HCV NAT was required as a supplemental test prior to a second FDA-licensed anti-HCV assay; if ID-HCV-NAT is reactive, no further testing is required. This study investigated the rate of low-level RNA in anti-HCV-reactive donation samples prior to and following the implementation of supplemental ID-HCV NAT. Study Design/Methods A retrospective analysis was conducted on frozen plasma unit samples from 1161 anti-HCV confirmed-positive/HCV-NAT-nonreactive donations collected from December 2014 to January 2020. Samples were tested by multiple replicates on the Grifols Procleix Ultrio Elite (UE) assay and corresponding discriminatory HCV (dHCV) assay on the Procleix Panther System. Prospectively, the prevalence of low-level RNA in 2912 anti-HCV-reactive donations detected through routine screening from April 2020 through March 2021 was determined. Results In retrospective analyses, 10 (0.86%) of 1161 plasma samples were UE reactive, of which four (0.34%) were dHCV reactive (in all replicates of UE and dHCV). Of 2912 anti-HCV-reactive donation samples testing NAT-nonreactive via routine MP-NAT, three (0.1%; 95% CI: 0.04-0.30) were dHCV reactive; 37% of the remaining samples were reactive by a second anti-HCV assay and thus serologically confirmed. Conclusions Retrospective and prospective analysis in comparison to earlier studies revealed that low-level HCV-RNA reactivity is decreasing over time. The very low HCV-RNA rates may be due to the widespread use of highly effective, direct-acting anti-viral treatments for those diagnosed with HCV infection.


  • Open Access

    Clinical evaluation of the Procleix SARS-CoV-2 assay, a sensitive, high-throughput test that runs on an automated system

    by Silvia Sauleda, Lourdes Palacios, Vanessa Brès, Maria Piñana, Lorena Alonso-Hernandez, Marta Bes, Maria Piron, Edurne Entrena, Antonio M. Minguez-Micolau, Jose Maria Marimón, et al.